Holen Sie sich die Stockscreener-App
25.81
2.42%
-0.64
Handel nachbörslich:
25.81
Schlusskurs vom Vortag:
$26.45
Offen:
$26.44
24-Stunden-Volumen:
582.36K
Relative Volume:
0.69
Marktkapitalisierung:
$1.26B
Einnahmen:
$681.75M
Nettoeinkommen (Verlust:
$70.47M
KGV:
17.80
EPS:
1.45
Netto-Cashflow:
$173.19M
1W Leistung:
-4.90%
1M Leistung:
+11.73%
6M Leistung:
+49.36%
1J Leistung:
-5.15%
1-Tages-Spanne:
$25.59
$26.44
1-Wochen-Bereich:
$25.59
$27.98
52-Wochen-Spanne:
$11.16
$31.67
Pacira Biosciences Inc Stock (PCRX) Company Profile
Firmenname
Pacira Biosciences Inc
Sektor
Telefon
813-553-6680
Adresse
5401 WEST KENNEDY BOULEVARD, TAMPA, NJ
Vergleichen Sie PCRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
25.81 | 1.26B | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
158.06 | 68.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.38 | 47.71B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.63 | 46.12B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.39 | 18.55B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
298.70 | 13.40B | 2.76B | 1.11B | 898.10M | 22.77 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-30 | Hochstufung | Truist | Sell → Hold |
| 2024-08-13 | Herabstufung | Truist | Buy → Sell |
| 2024-08-12 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2024-08-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-07 | Fortgesetzt | JP Morgan | Overweight |
| 2023-12-20 | Eingeleitet | Raymond James | Outperform |
| 2023-08-03 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | Fortgesetzt | Wedbush | Outperform |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-01-03 | Fortgesetzt | JP Morgan | Overweight |
| 2021-07-26 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-04-21 | Fortgesetzt | JP Morgan | Neutral |
| 2021-04-09 | Eingeleitet | Berenberg | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-02-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | Bestätigt | Needham | Buy |
| 2020-05-27 | Eingeleitet | Guggenheim | Neutral |
| 2020-04-07 | Eingeleitet | Northland Capital | Outperform |
| 2020-03-20 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-24 | Eingeleitet | SunTrust | Buy |
| 2020-01-23 | Eingeleitet | SunTrust | Buy |
| 2019-11-06 | Eingeleitet | BTIG Research | Buy |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-05-06 | Hochstufung | Mizuho | Underperform → Neutral |
| 2019-05-02 | Hochstufung | Stifel | Sell → Hold |
| 2019-02-01 | Herabstufung | Mizuho | Neutral → Underperform |
| 2018-08-06 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-21 | Bestätigt | Mizuho | Neutral |
| 2018-02-16 | Herabstufung | Needham | Buy → Hold |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-01-04 | Bestätigt | Canaccord Genuity | Buy |
| 2018-01-03 | Eingeleitet | Leerink Partners | Mkt Perform |
Alle ansehen
Pacira Biosciences Inc Aktie (PCRX) Neueste Nachrichten
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates - Yahoo Finance
Pacira BioSciences soars 52% following InvestingPro’s October Fair Value alert By Investing.com - Investing.com
(PCRX) Trading Advice - news.stocktradersdaily.com
BlackRock, Inc. Reduces Stake in Pacira BioSciences Inc - GuruFocus
How did Pacira BioSciences Inc (PCRX) fare last session? - uspostnews.com
Pacira BioSciences (PCRX) to Present Gene Therapy Study Results - GuruFocus
Pacira BioSciences to Present New Data on Clinical Immunogenicit - GuruFocus
Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis - GlobeNewswire
Revolutionary Gene Therapy Data: Pacira's New Approach Could Transform Knee Osteoarthritis Treatment - Stock Titan
Analysts Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Price Target at $26.67 - Defense World
Are Smart Investors Making the Right Decision? Pacira BioSciences Inc (PCRX) - Sete News
The Potential Rise in the Price of Pacira BioSciences Inc (PCRX) following insiders activity - knoxdaily.com
Analysts Estimate Pacira (PCRX) to Report a Decline in Earnings: What to Look Out for - Nasdaq
Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025 - GlobeNewswire
Leading Pain Management Company Pacira Sets Q1 2025 Earnings Call DateKey Details Inside - Stock Titan
LPL Financial LLC Purchases Shares of 13,321 Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacira BioSciences Inc (PCRX) Shares Up 3.97% on Apr 28 - GuruFocus
Pacira releases positive two-year data on knee osteoarthritis candidate - Seeking Alpha
Pacira BioSciences' Gene Therapy Shows Long-Term Improvement in Knee Osteoarthritis Symptoms - marketscreener.com
Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee - GlobeNewswire
Invesco Ltd. Cuts Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Zacks Research Issues Pessimistic Outlook for PCRX Earnings - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Pacira BioSciences Inc (NASDAQ:PCRX)’s 12-Month Price Target Currently Stands At 48 - Marketing Sentinel
Do investors need to be concerned about Pacira BioSciences Inc (PCRX)? - uspostnews.com
Pacira BioSciences Inc [PCRX] Officer makes an insider purchase of 500 shares worth 11625.0. - knoxdaily.com
Investors who hold shares of Pacira BioSciences, Inc. (NASDAQ: - openPR.com
Pacira BioSciences to Present 104-Week Efficacy Data - GlobeNewswire
Revolutionary Gene Therapy Shows 2-Year Effectiveness for Knee Arthritis After Single Dose - Stock Titan
Pacira BioSciences initiates $300M stock buyback - Investing.com
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday - Benzinga
Pacira BioSciences authorizes $300M share repurchase program - MSN
Pacira BioSciences (PCRX) Enhances Shareholder Value with Capita - GuruFocus
Pacira BioSciences (PCRX) Enhances Shareholder Value with Capital Allocation Strategy - GuruFocus
DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization As A Meaningful Step To Enhance Value For Shareholders - marketscreener.com
DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders – Company AnnouncementFT.com - Financial Times
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Bank of Montreal Can - Defense World
Pacira's Largest-Ever $300M Buyback Signals Major Growth PhaseKey Investor Catalyst Revealed - Stock Titan
Pacira BioSciences, Inc. (NASDAQ:PCRX) Stock Holdings Lifted by Geode Capital Management LLC - Defense World
(PCRX) Investment Analysis and Advice - news.stocktradersdaily.com
Pacira BioSciences initiates $300 million buyback plan By Investing.com - Investing.com India
Pacira Biosciences announces $300M share repurchase program - MSN
Pacira (PCRX) Announces New $300M Share Repurchase Plan | PCRX Stock News - GuruFocus
Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders - The Manila Times
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Shareholders to Inquire about Securities Investigation - markets.businessinsider.com
Pacira Biosciences IncAuthorizes $300 Million Share Repurchase Program - marketscreener.com
Pacira Biosciences Approves $300M Share Buyback - MarketWatch
Pacira BioSciences initiates $300 million buyback plan - Investing.com
Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders | PCRX Stock News - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Shareholders to Connect - markets.businessinsider.com
Is Pacira BioSciences, Inc. (PCRX) the Best Pharma Stock to Buy for Long Term Growth? - Yahoo Finance
Finanzdaten der Pacira Biosciences Inc-Aktie (PCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.03%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):